WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a medical stage biotechnology firm pioneering the event of novel oncolytic immunotherapies, in the present day introduced that members of the Replimune administration group will current on the forty third Annual J.P. Morgan Healthcare Convention on Monday, January 13, 2025 at 2:15 PM PT.
A simultaneous webcast shall be out there within the Traders part of Replimune’s web site at replimune.com. A replay shall be out there for 30 days following the convention.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was based in 2015 with the mission to rework most cancers therapy by pioneering the event of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is predicated on a potent HSV-1 spine supposed to maximise immunogenic cell dying and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have distinctive twin native and systemic exercise consisting of direct selective virus-mediated killing of the tumor ensuing within the launch of tumor derived antigens and altering of the tumor microenvironment to ignite a robust and sturdy systemic response. The RPx product candidates are anticipated to be synergistic with most established and experimental most cancers therapy modalities, resulting in the flexibility to be developed alone or mixed with quite a lot of different therapy choices. For extra info, please go to replimune.com.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
Supply: Replimune Group Inc (NASDAQ:)
